Long-term clinical outcome, therapy and mild mitochondrial dysfunction in hyperprolinemia.

Area of Science:

• Biochemistry
• Genetics
• Neurology

Background:

• Hyperprolinemia type II presents a distinct metabolic profile often associated with neurological involvement, yet the causal link between metabolic anomalies and clinical manifestations remains debated.
• Investigating disease frequency and neuro-metabolic outcomes requires comprehensive analysis of patient data, including metabolic profiles, clinical features, and genetic factors.
• Understanding the role of mitochondrial dysfunction in hyperprolinemia necessitates evaluating enzyme activities, ATP production, and clinical scores for mitochondrial disease.

Observation:

• A review of 20,991 urinary organic acid profiles identified four patients with hyperprolinemia type II and one with type I.
• Children with hyperprolinemia type II exhibited low-normal vitamin B6 levels and biochemical markers suggestive of mitochondrial dysfunction, confirmed in one case via muscle biopsy.
• All affected children experienced seizures and significant behavioral issues, including anxiety and hallucinations; two adolescent patients also had intellectual disability.

Findings:

• Hyperprolinemia type II is a rare inborn error of metabolism.
• Mitochondrial dysfunction is implicated in hyperprolinemia type II, alongside neurological and behavioral symptoms.
• The clinical course of hyperprolinemia type II appears non-progressive and independent of vitamin B6 levels or therapy.

Implications:

• Individuals diagnosed with hyperprolinemia require close monitoring for neurological and behavioral complications.
• Further research into the mechanisms linking metabolic abnormalities, mitochondrial dysfunction, and neurological symptoms in hyperprolinemia is warranted.
• This study highlights the importance of a multidisciplinary approach in managing rare metabolic disorders like hyperprolinemia.